Sr. VP Michael F. Huang sells 14,583 shares at blended avg $69.51 for $1.0M, reducing stake by 28.4%
Michael F. Huang, Sr. VP of Clinical Development, executed 9 separate sales totaling 14,583 shares for $1,013,627.06 on 2025-03-27, reducing his holdings from 51,400 to 36,817 shares. The sales were conducted at prices ranging from $65.97 to $72.64, with a blended average of $69.51, near the current price of $71.45 and close to the 52-week high of $71.99. This represents a substantial 28.4% reduction in his stake. The transaction occurs in the context of SLNO's stock having risen 46.4% over 30 days and 59.0% over 90 days, while the company remains unprofitable with a net income of $-76,616,000.00 for the most recent full fiscal year. The magnitude and scope of this sale warrants investor attention given the executive's senior role in clinical development and the timing relative to recent significant price appreciation.